PortalPublikationenSecondary malignancies in chronic myeloid leukemia patients ...

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Standard

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. / Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, G M; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; Flasshove, M; Rendenbach, B; Hofmann, W-K; Müller, M C; Pfirrmann, M; Hochhaus, A; Hasford, J; Hehlmann, R; Saußele, S.

in: LEUKEMIA, Jahrgang 30, Nr. 6, 06.2016, S. 1255-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miranda, MB, Lauseker, M, Kraus, M-P, Proetel, U, Hanfstein, B, Fabarius, A, Baerlocher, GM, Heim, D, Hossfeld, DK, Kolb, H-J, Krause, SW, Nerl, C, Brümmendorf, TH, Verbeek, W, Fauser, AA, Prümmer, O, Neben, K, Hess, U, Mahlberg, R, Plöger, C, Flasshove, M, Rendenbach, B, Hofmann, W-K, Müller, MC, Pfirrmann, M, Hochhaus, A, Hasford, J, Hehlmann, R & Saußele, S 2016, 'Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV', LEUKEMIA, Jg. 30, Nr. 6, S. 1255-62. https://doi.org/10.1038/leu.2016.20

APA

Miranda, M. B., Lauseker, M., Kraus, M-P., Proetel, U., Hanfstein, B., Fabarius, A., Baerlocher, G. M., Heim, D., Hossfeld, D. K., Kolb, H-J., Krause, S. W., Nerl, C., Brümmendorf, T. H., Verbeek, W., Fauser, A. A., Prümmer, O., Neben, K., Hess, U., Mahlberg, R., ... Saußele, S. (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. LEUKEMIA, 30(6), 1255-62. https://doi.org/10.1038/leu.2016.20

Vancouver

Miranda MB, Lauseker M, Kraus M-P, Proetel U, Hanfstein B, Fabarius A et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. LEUKEMIA. 2016 Jun;30(6):1255-62. https://doi.org/10.1038/leu.2016.20

Bibtex

@article{f416c2dfc13d4f7d84a144905b267c9e,
title = "Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV",
abstract = "Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment, especially carcinogenicity, has become a concern. We analyzed data of the CML study IV for the development of secondary malignancies. In total, 67 secondary malignancies were found in 64 of 1525 CML patients in chronic phase treated with TKI (n=61) and interferon-α only (n=3). The most common malignancies (n⩾4) were prostate, colorectal and lung cancer, non-Hodgkin's lymphoma (NHL), malignant melanoma, non-melanoma skin tumors and breast cancer. The standardized incidence ratio (SIR) for all malignancies excluding non-melanoma skin tumors was 0.88 (95% confidence interval (0.63-1.20)) for men and 1.06 (95% CI 0.69-1.55) for women. SIRs were between 0.49 (95% CI 0.13-1.34) for colorectal cancer in men and 4.29 (95% CI 1.09-11.66) for NHL in women. The SIR for NHL was significantly increased for men and women. An increase in the incidence of secondary malignancies could not be ascertained. The increased SIR for NHL has to be considered and long-term follow-up of CML patients is warranted, as the rate of secondary malignancies may increase over time.",
keywords = "Journal Article",
author = "Miranda, {M B} and M Lauseker and M-P Kraus and U Proetel and B Hanfstein and A Fabarius and Baerlocher, {G M} and D Heim and Hossfeld, {D K} and H-J Kolb and Krause, {S W} and C Nerl and Br{\"u}mmendorf, {T H} and W Verbeek and Fauser, {A A} and O Pr{\"u}mmer and K Neben and U Hess and R Mahlberg and C Pl{\"o}ger and M Flasshove and B Rendenbach and W-K Hofmann and M{\"u}ller, {M C} and M Pfirrmann and A Hochhaus and J Hasford and R Hehlmann and S Sau{\ss}ele",
year = "2016",
month = jun,
doi = "10.1038/leu.2016.20",
language = "English",
volume = "30",
pages = "1255--62",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

AU - Miranda, M B

AU - Lauseker, M

AU - Kraus, M-P

AU - Proetel, U

AU - Hanfstein, B

AU - Fabarius, A

AU - Baerlocher, G M

AU - Heim, D

AU - Hossfeld, D K

AU - Kolb, H-J

AU - Krause, S W

AU - Nerl, C

AU - Brümmendorf, T H

AU - Verbeek, W

AU - Fauser, A A

AU - Prümmer, O

AU - Neben, K

AU - Hess, U

AU - Mahlberg, R

AU - Plöger, C

AU - Flasshove, M

AU - Rendenbach, B

AU - Hofmann, W-K

AU - Müller, M C

AU - Pfirrmann, M

AU - Hochhaus, A

AU - Hasford, J

AU - Hehlmann, R

AU - Saußele, S

PY - 2016/6

Y1 - 2016/6

N2 - Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment, especially carcinogenicity, has become a concern. We analyzed data of the CML study IV for the development of secondary malignancies. In total, 67 secondary malignancies were found in 64 of 1525 CML patients in chronic phase treated with TKI (n=61) and interferon-α only (n=3). The most common malignancies (n⩾4) were prostate, colorectal and lung cancer, non-Hodgkin's lymphoma (NHL), malignant melanoma, non-melanoma skin tumors and breast cancer. The standardized incidence ratio (SIR) for all malignancies excluding non-melanoma skin tumors was 0.88 (95% confidence interval (0.63-1.20)) for men and 1.06 (95% CI 0.69-1.55) for women. SIRs were between 0.49 (95% CI 0.13-1.34) for colorectal cancer in men and 4.29 (95% CI 1.09-11.66) for NHL in women. The SIR for NHL was significantly increased for men and women. An increase in the incidence of secondary malignancies could not be ascertained. The increased SIR for NHL has to be considered and long-term follow-up of CML patients is warranted, as the rate of secondary malignancies may increase over time.

AB - Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment, especially carcinogenicity, has become a concern. We analyzed data of the CML study IV for the development of secondary malignancies. In total, 67 secondary malignancies were found in 64 of 1525 CML patients in chronic phase treated with TKI (n=61) and interferon-α only (n=3). The most common malignancies (n⩾4) were prostate, colorectal and lung cancer, non-Hodgkin's lymphoma (NHL), malignant melanoma, non-melanoma skin tumors and breast cancer. The standardized incidence ratio (SIR) for all malignancies excluding non-melanoma skin tumors was 0.88 (95% confidence interval (0.63-1.20)) for men and 1.06 (95% CI 0.69-1.55) for women. SIRs were between 0.49 (95% CI 0.13-1.34) for colorectal cancer in men and 4.29 (95% CI 1.09-11.66) for NHL in women. The SIR for NHL was significantly increased for men and women. An increase in the incidence of secondary malignancies could not be ascertained. The increased SIR for NHL has to be considered and long-term follow-up of CML patients is warranted, as the rate of secondary malignancies may increase over time.

KW - Journal Article

U2 - 10.1038/leu.2016.20

DO - 10.1038/leu.2016.20

M3 - SCORING: Journal article

C2 - 26859076

VL - 30

SP - 1255

EP - 1262

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 6

ER -